PODXL2 Expression Is Associated with Inferior Survival, Adverse-Risk Features, and Distinct Transcriptional Programs in Acute Myeloid Leukemia
Simple Summary Acute myeloid leukemia (AML) is a biologically diverse blood cancer with markedly different outcomes among patients. Current risk-classification systems do not fully capture this variability, highlighting the need for additional biomarkers that may refine risk stratification and prognostic assessment. In...